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ABSTRACT
THE EFFECTS OF OVARIAN HORMONES AND EXERCISE ON GENE MARKERS
OF CARDIAC DYSFUNCTION
MAY 2015
ANISHA S. PATEL, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Prof. Sarah Witkowski
Heart disease is the leading cause of death in women in the United States.
Premenopausal women appear to have better cardiac function and lower risk of heart
disease compared to male postmenopausal female counterparts. Ovarian hormone loss
influences blood pressure homeostasis and causes systemic inflammation, which may
result in chronic stress on the heart. Two key physiological changes in cardiac
dysfunction are reemergence of the fetal gene pattern and myocardial remodeling.
Physical activity has been linked to improved cardiac function. The purpose of this study
was to investigate the effects of ovariectomy on early markers of cardiac dysfunction and
fibrosis and to determine if voluntary physical activity alters expression patterns in
ovariectomized mice. We investigated the effects of ovariectomy and exercise on cardiac
expression of fetal genes and markers and mediators of fibrosis in two cohorts of 8-10
week old female mice. Ovariectomized mice had greater expression of cardiac fetal genes
and real time-PCR (RT-PCR) results indicated activation of the fibrosis pathway.
Exercise was able to influence the expression of some markers of cardiac dysfunction.
We concluded that ovarian hormone loss and associated physiological changes such as
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increased adiposity and systemic inflammation trigger early changes in cardiac gene
expression that precede overt cardiac dysfunction.
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CHAPTER 1
INTRODUCTION
Heart disease is the leading cause of death in women. Prior to menopause, women
tend to have better cardiac outcomes compared to men, exhibiting preserved contractility
with age and better responses to cardiac stressors such as hypertension and myocardial
injury (19, 66). After menopause, mortality rates from heart disease increase and
prognosis worsens. Most women who suffer from heart failure are postmenopausal and
more women over the age of 45 who have a heart attack die within 1 year compared with
men (29, 82).
The gender disparity associated with heart disease combined with the detrimental
effects of menopause on female cardiac health provides evidence of a possible
cardioprotective role of ovarian hormones. Ovarian hormone loss is linked to increased
adiposity, insulin resistance, and systemic inflammation (85). Estrogen-mediated
regulation of the renin-angiotensin-aldosterone system (RAAS) is lost after menopause,
resulting in RAAS hyperactivity and consequential problems with natriuresis and diuresis
(15, 34). Resulting blood pressure imbalance and increased hemodynamic load induce
bouts of ischemia and increase wall stretch on the heart. This disease environment closely
resembles the in utero environment of the growing fetal heart and is characterized by the
re-expression of a fetal gene pattern (84, 106). While this regression in gene transcription
has been well documented in models of acute cardiac injury or induced heart disease,
early changes in expression patterns of cardiac dysfunction markers in a model of ovarian
hormone loss have not yet been established (15, 84, 94).

1

In heart disease models, activation of the fetal gene pattern can exacerbate RAAS
activity, resulting in increased levels of intracardiac angiotensin II (AngII) (23, 87).
Acute injury or chronic stress can initiate an inflammatory response, cardiomyocyte
hypertrophy, and myocardial remodeling (10). The myocardium is comprised of a variety
of resident cells and AngII can trigger cardiac fibrosis through activation of cardiac
fibroblasts (CFB) (48, 58). Activated cardiac fibroblasts differentiate to myofibroblasts
(MFBs), cells that produce collagen and other ECM proteins, resulting in increased
fibrosis (24).
Estrogen supplementation has been shown to reduce negative remodeling of
myocardial tissue, indicating the hormone may have anti-fibrotic effects (70). Both
cardiac myocytes and fibroblasts express functional estrogen receptors and 17β-estradiol
has been shown to inhibit collagen synthesis in cardiac fibroblasts by downregulation of
AngII receptors (32, 125). To date, severe cardiac fibrosis and tissue remodeling has
been shown in models inducing acute injury or stress or have investigated the effects of
estrogen related to disease pathology in an aged model or induced cardiac dysfunction;
signs of cardiac tissue fibrosis at early stages of ovarian hormone loss without intentional
ischemia or cardiac injury have not been established.
Physical activity has been shown to decrease the risk for heart disease. Exercise is
linked to reduced cardiac dysfunction and attenuation for pathological remodeling (51).
Recent studies have also shown exercise may decrease cardiac fibrosis attributed to low
estrogen levels (70). Preliminary data from our lab has shown that physical activity
influences a possible inflammatory and fibrotic response to low ovarian hormone levels
in the heart. Understanding potential benefits of exercise on cardiac function in an
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ovariectomy model may provide alternatives to hormone therapy, a controversial
treatment for postmenopausal women.
The specific aims and hypotheses for this study have been outlined below:

Aim 1: To study the effects of ovariectomy on the markers of disease in mouse heart
tissue.
Hypothesis 1: The hearts of ovariectomized (OVX) mice will exhibit evidence of
dysfunction via a fetal gene expression pattern compared with sham surgery
(SHAM) hearts.
Aim 2: To study the effects of ovariectomy on gene expression patterns that indicate
fibrosis in mouse heart tissue.
Hypothesis 2: OVX mice will express more cardiac profibrotic markers and will
exhibit more extracellular matrix (ECM) protein deposition compared with
SHAM counterparts.
Aim 3: To determine whether exposure to voluntary wheel running physical activity
(EX) influences markers of cardiac dysfunction and fibrosis associated with ovariectomy.
Hypothesis 3A: EX mice will exhibit lower expression of cardiac fetal gene
markers compared with sedentary (SED) counterparts.
Hypothesis 3B: EX mice will exhibit lower cardiac ECM gene expression
compared with SED counterparts.
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CHAPTER 2
LITERATURE REVIEW
2.1 Introduction
This literature review will highlight the prevalence of heart disease in women and
the importance of studying the increase in risk that is associated with menopause.
Changes in ovarian hormone levels will be assessed as key risk factors; and the
relationship between ovariectomy, the cardiac fetal gene program, and fibrosis will be
detailed. Lastly, the influence of exercise on heart disease pathology and dysfunction will
also be explored.
2.2 Heart Disease & Women
2.2.1 Prevalence and Pathology
Heart disease is currently the leading cause of death in women. In 2010, Direct
and indirect costs associated with heart disease exceeded $300 billion (29). According to
CDC data from 2009, one in four female deaths was caused by heart disease in the United
States (56). This statistic increased to 1 in 3 female deaths by 2013 and will likely
augment with the increasing prevalence of factors associated with heart disease such as
hypertension, diabetes, obesity, and high cholesterol (73, 74). The increase in the aging
population is also a significant risk factor as individuals over the age of 65 have a greater
risk of stroke, myocardial infarction, coronary heart disease (CHD), hypertension, and
heart failure (37).
Sex differences have been shown in a variety of heart and heart disease-related
outcomes. While women preserve myocyte number and size with age, male myocardial
mass decreases as a result of a reduction in the number of myocytes, and this loss of mass
4

leads to compensatory myocyte hypertrophy (78). This pathological hypertrophy results
in decreased systolic function and increased left ventricle diameter over time (31).
Chamber dilation and wall thinning result in poor cardiac contractility in males, while
contractility is better preserved in females with age (14, 19). Premenopausal women fare
better in response to hypertension, aortic stenosis, hypertrophic cardiomyopathy, and
acute myocardial ischemia compared to their male counterparts (66, 82). Premenopausal
women also appear to have better diastolic function than men, although diastolic function
decreases in both sexes with age (31, 78). Gender disparities regarding heart health and
function indicate that females have cardioprotection prior to menopause, potentially from
ovarian hormones.
The contribution of ovarian hormones to cardiac pathology, function, and
outcomes is evident when comparing pre- and postmenopausal women. Most women that
suffer from heart failure are postmenopausal (82). After menopause, female mortality
rates due to heart disease increase significantly and surpass those of men (Figure 1) (28,
97). Given the increases in the elderly population, women past menopause will have a
direct impact on the prevalence of heart disease and heart disease associated costs. After
65, the incidence of heart failure nears 10 per 1000 people and American Heart
Association projections show that by 2030, the prevalence of heart failure will increase
by 25% (29). The prevalence of CVD, hypertension and heart failure increases drastically
in women and surpasses prevalence in male counterparts with age (Figure 2) (17). The
increase in risk associated with menopause combined with the dramatic increases in size
of the elderly population pose a significant problem regarding the health burden and
treatment costs in the United States.
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Figure 1: CVD mortality trends for males and females (United States:1979-2010) {{354
Go,A.S. 2014}}.

Figure 2: Prevalence of cardiovascular disease (CVD) in adults ≥ 20 years of age (NHANES
2007-2010). Source National Heart, Lung, and Blood Institute {{355 Anonymous 2012}}.

The reduction in circulating ovarian hormones that accompanies menopause is
linked to an increased risk for heart disease, indicating that ovarian hormones may be
cardioprotective (66). The direct effects of ovarian hormone reduction on heart health
6

have not been thoroughly assessed although some literature suggests that cardioprotective
effects of the ovarian hormone estrogen (E2) include decreased cardiac inflammation and
pathological remodeling (55). For example, ovariectomization in mice, a model used to
study postmenopausal physiology, results in greater left ventricular hypertrophy in
response to pressure overload compared with ovariectomized mice supplemented with
17β-estradiol, indicating that E2 may be involved in pathways regulating pathological
hypertrophy (110).
To date, most investigations have initiated heart disease pathology through drastic
interventions such as trans aortic constriction, ischemia, or other interventions that induce
rapid hypertension and cardiac hypertrophy (24, 49, 122). These methods, while
effective, accelerate heart failure and do not provide data on subtle changes in cardiac
health and signaling that result solely from reduced ovarian hormones.
2.2.2

Ovarian Hormones
The two main hormones secreted by the ovaries are estradiol/estrogen and

progesterone. Minor concentrations of E2 are also secreted by adipose tissue, skin,
muscle and endometrial tissue. Carrier proteins bind to and transport about 99% of
circulating E2s while the unbound 1% is considered physiologically active. E2s are
steroid hormones that act on E2 receptors (ERs). Membrane E2 receptor activation can
trigger signaling pathways in the cell or result in a conformational change in the protein
that initiates downstream events in the nucleus via transcription factor activation or
inhibition (26, 77). Additionally, E2 can induce genomic effects by binding to receptors
in the cell nucleus (77). The two main ERs, ER-α and ER-β, act via the nongenomic
pathway when activated by E2. These receptors exhibit different actions in the

7

cardiovascular system. In general, ER-α prevents vascular smooth muscle cell
proliferation while ER-β regulates pathologic cardiac hypertrophy (54). Both receptor
types are found in cardiac myocytes. An animal study showed that ovariectomized mice,
aged mice, and aged ovariectomized mice had similar densities of ERs compared to sham
surgery mice (104). Thus, prevalence of ER-α and ER-β do not appear to be influenced
by not ovariectomy or aging.
Progesterone is another steroid hormone secreted by the ovaries and is well
known for its function in pregnancy to prepare the endometrial lining for the fetus;
however limited research has been conducted on the cardiovascular effects of
progesterone independently of E2 (18). Progesterone binds to two main receptors, PR-A
and PR-B, affecting gene expression and protein phosphorylation. Like E2, progesterone
is also able to initiate signaling cascades or influence gene activity via cell membrane or
nucleic PRs (26). Both of these receptors are found in cardiac tissue, indicating
progesterone has potential influence on cardiac function; however evidence is equivocal
regarding their effect. High serum levels of progesterone in men and women are
associated with increased risk for congestive heart failure and in vivo animal studies have
found progesterone causes inotropic dysfunction, or problems with contractility, although
other studies have shown no effect of progesterone on contraction (76, 116).
While progesterone and E2 combination therapy is related to increased risk for
non-cardiovascular events in women with prior heart disease, these hormones in
combination appear to reduce risk for heart disease and benefit cardiac function in
healthy postmenopausal women (40). A longitudinal study conducted on healthy
postmenopausal women observed the effects of hormone replacement therapy (HRT)
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with E2-only supplementation, E2 and progesterone in combination, and placebo. E2
alone or in combination with progesterone improved lipoprotein and reduced fibrinogen
levels (116). Another study found that postmenopausal women with 4 months of
combined hormone replacement therapy exhibited improved indicators of cardiac systolic
and diastolic function including cardiac output, stroke volume, ejection fraction, and end
diastolic volume (98).
The influence of HRT on coronary heart disease risk was investigated by the
Heart and estrogen/progestin Replacement Study (HERS), the first large randomized,
double-blind placebo controlled study to examine this relationship; Hulley et al., found
that hormone replacement therapy was not cardioprotective as placebo and HRT
participants developed similar numbers of heart problems over 4 years between
controlled clinical time points. Additionally, more HRT participants experienced
coronary events during the first year of the study compared to placebo group (41). A
study by the Women’s Health Initiative aimed to determine if HRT could prevent CHD
and participants were to be followed over an 8-year period. After 5 years the study was
halted as a disproportionate number of participants on HRT began to develop breast
cancer. Data analysis at this point found a significant association (p=0.05) between HRT
and CHD, stroke, breast cancer, and pulmonary embolism (16, 88). Due to the
uncertainty regarding the influence of HRT on cardiac health and the high risks
associated with HRT, other methods of treatment like exercise should be investigated.
2.3 Evaluating Cardiac Pathology: The Fetal Gene Program
In order to understand the increased risk for heart disease in postmenopausal
women, the effects of ovarian hormone loss on the heart tissue must be studied. Initial
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signs of menopause-induced stress in the heart tissue that precede outward cardiac
dysfunction, such as poor contractility or hypertrophy, have not been established. The
fetal gene program is a pattern of mRNA expression that is indicative of cardiac
dysfunction in adults. An adult heart experiences bouts of ischemia, increasing
hemodynamic load, and hypertrophy in a disease state, much like a fetal heart in utero. In
response to chronic stress or acute injury, the adult heart begins to revert expression of
cardiac genes associated with stretch and hypoxia from the healthy archetype to a disease
pattern that resembles fetal expression (84).
In utero, the fetal heart exhibits gene expression patterns and a metabolic system
that differ from the post natal, healthy adult heart. In the low oxygen environment of the
uterus, the heart metabolizes carbohydrates such as glucose and lactate (25). After the
stress of birth and a 24-hour exposure to an environment rich in oxygen, the post natal
heart begins to shift the metabolic paradigm and relies primarily on fatty acid oxidation
for energy (64). The fetal heart also experiences growth-induced stretch characterized by
upregulation of cardiac hormones responding to stretch like atrial natriuretic peptide
(ANP) and beta natriuretic peptide (BNP) (42, 84). Compared to fetal expression, these
stretch-related hormones are downregulated in the healthy adult heart (44, 107). Under
postnatal physiological conditions, atrial cardiomyocites express ANP while BNP mRNA
is found in both atrial and ventricular tissue (12, 65, 123). These hormones function to
reduce blood pressure by regulating natriuresis and diuresis, and inhibiting activation of
the renin-angiotensin-aldosterone system (RAAS) (3, 75).
Apart from stretch hormone activation, gradual increases in hemodynamic load
are also accompanied by a transition in cardiac muscle fiber expression. Initially, the pre-
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natal heart expresses the sarcomeric protein α-skeletal actin whereas the adult heart
primarily expresses α-cardiac actin (93). Both isoforms are structurally similar, differing
in only 4 four protein residues; however the transition from skeletal to cardiac actin is a
characteristic difference between the fetal and adult heart (43). The murine fetal heart is
also characterized by expression of β-myosin heavy chain (β-MHC) and this contractile
element transitions to the α isoform (α-MHC) after birth. Humans, however, express βMHC in cardiac tissue throughout fetal development as well as adulthood (91, 92).
Additionally, the growing fetal heart slowly develops its inotropic pattern, gradually
increasing expression of Calcium ATPase (SERCA-2a), a calcium handling protein.
SERCA-2a allows for muscle relaxation by enabling the re-uptake of calcium into the
sarcoplasmic reticulum after contraction. After birth, the established levels of SERCA-2a
are maintained throughout adulthood (8, 84).
In a disease state, the adult heart is exposed to stressors that resemble the stimuli
of the in utero environment. Bouts of ischemia induce periods of hypoxia and the heart
experiences stretch in response to increased hemodynamic load. The heart reacts to these
disease-related changes by reverting to a fetal heart pattern of metabolism (5, 84, 107).
The failing adult heart has glycogen stores comparable to the fetal heart indicating that
disease may activate a switch to a metabolic pattern that relies on glucose as a substrate
(11). Chronic stress and the increased hemodynamic load exacerbates myocardial wall
strain resulting in the upregulation of stretch hormones ANP and BNP; overall levels of
BNP mRNA increase and ventricles are recruited to synthesize ANP (42, 90). Greater
levels of cardiac ANP and BNP also function systemically to hormonally regulate RAAS
activation in the kidneys and prevent increases in blood pressure (15).
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As disease induced hypertrophy progresses, the heart reverts back to increased
expression of α-skeletal actin and downregulation of the formerly predominant cardiac
isoform (5, 42, 107). Expression of α-MHC is also downregulated in response to heart
disease, while β-MHC levels are preserved, resulting in an isoform shift that resembles
the fetal expression pattern in rodents. While human adult hearts only express β-MHC,
these levels decrease with disease (84, 91, 92). Cardiac stress also affects calcium
handling in the heart tissue, in models of induced pressure overload or severe hypoxia,
SERCA-2a expression is reduced or diminished entirely (42, 84, 107). McMullen et al.
used a mouse model of pathological pressure overload to characterize the expression
pattern of fetal genes. The Northern blot in Figure 2 shows the difference in cardiac
mRNA expression between an aortic banding model of pressure overload (BAND) and
rats that underwent a sham surgery (SHAM). The BAND group, exhibited a pathological
response to the pressure overload with greater expression of ANP, BNP, β-MHC, and αska, resembling the expression pattern established in developing fetal hearts (5, 71).

Figure 3: Ventricle RNA expression of fetal genes in pressure overload model
(Band) exhibited an increase in markers responding to mechanical stretch and a
decrease in contractile function markers compared to control (Sham) {{358
McMullen,J.R. 2003; 180 Bernardo,Bianca C. 2010}}.

12

2.4 Fibrosis
In response to chronic stress or acute injury, the myocardium begins to remodel.
Increased peripheral resistance forces the heart tissue to stretch and as this pathological
hypertrophy occurs, the distance between adjacent myocytes and other resident cells
increases. The heart tissue compensates for this growth with fibrotic remodeling as cells
increase secretion of ECM fibers and the matrix thickens. This process of malignant
fibrosis is a combined effort of a variety of cardiac cell types.
Cardiac fibroblast (CFBs) cells make up 27% of the murine heart and 40%-60%
of the adult human heart (96, 100). Forming a three-dimensional structure around cardiac
myocytes, fibroblasts serve to maintain structural integrity of the heart tissue. More
importantly, CFBs regulate extracellular matrix homeostasis by controlling ECM protein
turnover rate (120). Acute injury or chronic stress conditions induce a fibroblast signaling
response that serves to heal the injury or compensate for the increased load. In a stressed
environment, often caused by increased peripheral resistance or systemic inflammation,
cardiac fibroblasts differentiate into a new cell type with properties that resemble a
combination of fibroblasts, smooth muscle cells, and vascular pericytes (10, 36). This cell
type, known as the myofibroblast (MFB), is associated with pathology. Current research
hypothesizes that in a disease state, quiescent (or inactive) CFBs along with other
resident precursor cells, also differentiate into MFBs (10).
Initially the CFB becomes a proto-myofibroblast (proto-MFB), which is
characterized by increased cytoplasmic actin stress fiber production and the formation of
a dense matrix of collagen and fibronectin fibers (10, 108). Stage two of myofibroblast
formation occurs as the protein transforming growth factor beta-1 (TGFβ-1) binds to its
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receptor, acting on a kinase enzyme to phosphorylate SMAD proteins (SMAD 2 and 3).
These proteins form a complex and translocate to the nucleus of the proto-MFB in order
to activate transcription of genes coding for profibrotic proteins. MFBs increase the
production of fibronectin and collagen (I and III) and begin to produce and secrete the
ECM protein vimentin, resulting in a denser, fiber rich matrix (81, 120). During this
differentiation process, MFBs also begin to express endothelin-1 (ET-1) which
participates in a positive feedback loop to promote MFB formation. ET-1 also stimulates
the production of α–SMA (α-smooth muscle actin), a key indicator that the cell has
reached the second stage of MFB formation (22, 81).
Acute injury and chronic stress are hypothesized to induce this MFB formation
through different pathways. Acute injury, such as a myocardial infarct, initiates a wound
healing response in the heart that promotes cardiac fibrosis. White blood cells and
macrophages infiltrate the infarct area and initiate an inflammatory response. Secretion of
TGFβ-1 by the pro-inflammatory cells phosphorylates SMAD proteins in fibroblasts,
resulting in MFB formation, migration, and ECM protein deposition (4, 68). TGFβ-1 can
also act through non-canonical mechanisms via the JNK and p38 kinase pathways (9, 58,
59). Chronic stress, like the systemic inflammation that accompanies increased
postmenopausal adiposity, is characterized by the prevalence of pro-inflammatory
cytokines in the blood and perturbations to blood pressure homeostasis. This stress is
hypothesized to induce MFB formation in the heart via the renin-angiotensin system (10).
In a healthy heart the local natriuretic peptide system shares an inverse
relationship with the systemic RAAS although this balance is lost in disease. In a healthy
individual, the kidneys respond to low sodium levels, low blood volume and blood
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pressure by releasing renin, a protease that leads to angiotensin II production, increased
sodium and fluid retention and vasoconstriction to regain pressure homeostasis. On the
other hand, with increased blood pressure and cardiac stretch, ANP and BNP are released
and induce vasorelaxation, natriuresis and diuresis. In addition, ANP suppresses renin
secretion producing an overall effect of reducing blood pressure and pressure on the
myocardium (15, 95). On the other hand, in many pathological circumstances, increases
in plasma levels of renin is accompanied by ANP and BNP upregulation in cardiac tissue
in an attempt to prevent RAAS hyperactivity (15). In vitro research has also shown that
ANP acts to protect the heart from pathological remodeling in that it inhibits TFGβinduced SMAD signaling and prevents MFB transformation in response to pressureoverload (62). Li et al. also found that ANP-null mice exhibited increased alpha-smooth
muscle actin expression and colocalization with collagen deposits, indicating that low
levels of natriuretic peptides are associated with greater pathological CFB differentiation,
increased cardiac hypertrophy and pathological remodeling (62). Therefore, the
activation of ANP occurs in an attempt to protect the heart from pressure overload and
negative remodeling.
Recent studies have found that apart from the systemic role in RAAS, angiotensin
II plays a direct role in hypertrophy and remodeling of the heart. Systemic renin
accumulation in the heart increases intracardiac angiotensin II formation. High levels of
cardiac angiotensin II exacerbate diastolic dysfunction, myocyte hypertrophy, and tissue
fibrosis (39). Cardiac angiotensin II (AngII) is an upstream inducer of TGFβ-1 signaling
in fibrosis (6, 7, 35, 58). In response to higher levels of local AngII, fibroblasts increase
TGFβ-1 synthesis, promoting CFB differentiation to an MFB phenotype (7, 9, 10).
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Myofibroblast proliferation and increased extracellular matrix fiber deposition
causes pathological structural changes in the heart. As a result, heart contractile function
is altered. Excess protein deposition in the ECM increases the distance between adjacent
cardiac muscle cells which hinders proper contractility and increases wall stiffness (24,
124). Recent in vitro studies show that myofibroblasts exhibit increased intercellular
signaling after differentiation, which may be a compensatory mechanism for the
pathological effects of myocardial remodeling (124). Ovarian hormones such as E2 act
directly on fibroblast differentiation pathways in response to cardiac hypertrophy. Mouse
model studies show that ovariectomized mice, develop greater left ventricular
hypertrophy as a response to pressure overload compared to ovariectomized mice
supplemented with 17β-estradiol, indicating that E2 may be involved in pathways
regulating hypertrophy (110). Both cardiac myocytes and fibroblasts express functional
E2 receptors and 17β-estradiol has been shown to inhibit collagen synthesis in cardiac
fibroblasts by downregulation of AngII receptors (32, 125). In response to
ischemia/reperfusion, E2 improves cardiac recovery by downregulating inflammatory
factors like tumor necrosis factor alpha (TNF-α) (122). Just as E2 supplementation allows
for a better response to cardiac injury, E2 loss associated with menopause could have
detrimental effects on heart health. Investigating the mechanisms underlying cardiac
fibrosis may provide insight to the effects of menopause on female cardiac function.
As pathological cardiac fibrosis progresses, myocardial structure regulation is
affected. Fibroblast proliferation and hyperactivity alters transcription of matrix
metalloproteinases (MMP) and their tissue inhibitors (TIMPS), which normally maintain
ECM homeostasis (48, 109). MMP activation has mostly been established as a response
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to acute injury or in models of acutely induced cardiac hypertrophy (102, 103). MMP
activity is also regulated by inflammatory biomarkers AngII and ET-1 (109). In vitro
experiments of male and female Wistar rat cardiac fibroblasts observed the effects of E2
supplementation as well as E2 receptor (ER) antagonists on MMP-2 expression. 17βestradiol supplementation inhibited MMP-2 expression via activation of E2 receptor α
(ERα). The study found that activated ERα acts via the ERK 1/2 pathway to
phosphorylate Elk-1, which downregulates MMP-2 gene transcription (67). The influence
of E2 on fibroblast expression of MMPs and overall activity suggests a mechanism linked
to sex-related differences in cardiac fibrosis (67). However, the involvement of MMP
activation at initial stages of disease is unclear.
2.5 Inflammation
Inflammation can be systemic or localized to specific tissues. Menopause is
related to increases in systemic inflammatory factors such as monocyte chemotactic
protein-1 (MCP-1), interleukin 1 beta (IL-1β), IL-10, and TNFα (60, 113). Systemic
inflammation after menopause may be in part a result of increased adiposity. Higher fat
deposition and insulin resistance are associated with the reduction in circulating ovarian
hormones that occurs after menopause (45). Ovariectomy in mice leads to significant
increases in body weight and fat mass. Interestingly, studies measuring food intake found
that ovariectomized mice did not consume more food than control (sham surgery) mice
(45, 86). In one of these studies, despite similar food intake, the ovariectomized mice
exhibited increased insulin resistance and gained 25% more weight than control mice
after 8 weeks. This increase in mass was accompanied by increased hepatic fat
deposition. Both visceral adipose tissue and lipid droplets in the liver exhibited increased
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expression of pro-inflammatory markers and white blood cell infiltration the
ovariectomized mice (86). Therefore, adipose tissue inflammation caused by ovarian
hormone reduction results in a systemic reaction, initiating an inflammatory response in
other tissues. A recent study reported that although ovariectomized mice became fatter at
12 weeks compared with control mice, by 20 weeks the groups were similar weight but
ovariectomized mice had more adipose tissue inflammation.

By week 26,

ovariectomized mice had more insulin-resistance compared with controls (111). These
studies demonstrate that ovarian hormone reduction expedites weight gain and fatty
deposition initially; although with time ovariectomy does not result in more weight gain
or fat deposition compared to control mice. The decrease in circulating ovarian hormones
associated with the loss of the ovaries appears to upregulate adipose-related inflammatory
markers and may result in an inflammatory response throughout the system.
Inflammation caused by risk factors for heart disease can also have direct
influences on cell death and tissue damage in the myocardium. Cardiac tissue responds to
low-grade stress with oxidative bursts, triggering the production of reactive oxygen
species (ROS) by local neutrophils as well as mitochondria and various oxidase enzymes
in the myocardium (69). Oxidative stress response causes platelet activation, endothelial
swelling, and neutrophil infiltration, disrupting blood flow and resulting in dysfunction of
cardiac endothelium (69, 112). This leads to reduced levels of nitric oxide, a common
vasodilator, and increased production of proinflammatory cytokines and adhesion
molecules (69).
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2.6 Physical Activity
Physical activity has been shown to improve cardiac function and reduce the risk
for heart disease. Exercise has been linked to reduced systemic inflammation,
inflammatory biomarkers, and circulating white blood cells (13, 47). A recent study
showed that exercise decreased negative remodeling in the hearts of spontaneously
hypertensive rats (70). Therefore, it is possible that physical activity may be able to
attenuate for the profibrotic outcomes associated with E2 loss and chronic inflammation.
Exercise may have a direct effect on the heart or may act indirectly by reducing systemic
inflammation.
Physical activity is also associated with physiological cardiac hypertrophy, though
this increase in heart mass is generally benign (5, 114). Resistance training and endurance
exercise induce concentric and eccentric myocyte hypertrophy, respectively, through a
pathway regulated by insulin-like growth factor 1 (IGF-1) (72, 114). Unlike pathological
remodeling, this physiological hypertrophy results in normal or enhanced cardiac
function that is exhibited by proportional chamber enlargement and improved
contractility (5). Additionally, physiological hypertrophy does not cause apoptosis or
alter gene expression of pro-inflammatory/profibrotic markers such as AngII and ET-1
(5, 114). In a study comparing pathological and physiological cardiac hypertrophy, Kemi
et al. found that 8-week old female mice, when aerobically trained (wheel running) for 6
weeks, exhibited cardiac myocytes that were approximately 20% longer and 30% wider
than those of the sedentary group. Furthermore, the trained group exhibited cardiac
hypertrophy via activation of the mTOR kinase pathway, with no increases in expression
of fetal genes ANP, BNP, and skeletal muscle actin. The disease model, created using
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transverse aortic constriction, also resulted in cardiac hypertrophy; however this
remodeling was accompanied by increased mRNA expression of ANP, BNP, and skeletal
muscle actin, indicating a pathological response (51). McMullen et al. also investigated
the physiological expression pattern of fetal genes in swim-trained rats. Figure 3 shows
difference between the pathological expression pattern (Band) and the physiological
expression pattern (Exercise) of the fetal gene program. Both Band and Exercise groups
exhibited cardiac hypertrophy although the hypertrophy in the Band group was
accompanied by hypertension and cardiac dysfunction while the exercise group exhibited
decreased resting heart rate and increased stroke volume, indicating enhanced cardiac
function (5, 71).

Figure 4: Ventricle RNA expression of fetal genes in physiological
hypertrophy model (Exercise) exhibited a diminished expression of
markers responding to mechanical stretch and an expression pattern of
contractile function markers similar to control (Sedentary) {{180
Bernardo,Bianca C. 2010; 358 McMullen,J.R. 2003}}.

Exercise-mediated hypertrophy is also reversible and does not involve myocardial
remodeling, while hypertrophy associated with heart disease is irreversible and results in
WBC infiltration, ECM protein deposition, fibrosis, and eventual heart failure (114).
These principal differences between physiological and pathological hypertrophy
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distinguish disease-mediated mechanisms and exercise-induced changes in myocardial
structure.
Physical
influence

key

activity

may

inflammatory

markers in an ovariectomy model.
In a preliminary study from our
lab, hearts from female C57/BL6
mice were analyzed for gene
expression

of

inflammatory

markers. Mice were divided into
four groups: OVX, OVX+EX, SHAM

Figure 5: Interleukin-1α cardiac gene expression. *
Significantly different from ovariectomized (OVX) female
mice.

and SHAM+EX. Both OVX and OVX+EX mice underwent a bilateral ovariectomy. For
8 weeks, these groups were housed in cages and the +EX mice were provided voluntary
exercise on a running wheel.
Preliminary

data

showed

exercise-exposed mice exhibited
significantly lower cardiac gene
expression of IL1-α, a proinflammatory marker, compared

Figure 6: Plasminogen activator inhibitor-1 (PAI-1) cardiac
gene expression. * Significantly different from sham surgery
(SHAM) female mice, + Significantly different from
ovariectomized (OVX) female mice.

to OVX (Figure 4).

IL1-α is
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activated

macrophages,

endothelial cells and causes the proliferation of fibroblasts.
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The cardioprotective effects of exercise may play a role in other inflammatory
marker levels. Plasminogen activator inhibitor-1 (PAI-1) functions to prevent
fibrinolysis, or the degradation of blood clots, and is associated with CVD development
(30). Plasma levels of PAI-1 have been shown to be significantly decreased after shortterm aerobic training in postmenopausal women (46). In addition to an exercise effect on
IL1-α levels in our preliminary study, mice exposed to physical activity had lower PAI-1
cardiac gene expression compared to their sedentary counterparts (Figure 5). More
research must be conducted in order to see the effects of exercise on inflammation and
cardiac fibrosis.
2.7 Overview
Common risk factors associated with heart disease induce RAAS activation and
myocyte hypertrophy during the initial stages of pathological remodeling of the heart.
RAAS activation and chronic cardiac stress may effect fetal gene expression patterns in
the heart. Over time, the heart is unable to compensate for continuous overload and
fibrotic pathways are activated. Ovarian hormones interact with multiple factors involved
in the RAAS system as well as pathological remodeling pathways in the heart. The
eventual increase in ECM protein deposition and fibrosis that result from this remodeling
cause decreased contractility and cardiac dysfunction, which results in heart failure.
The following study evaluates pathways implicated in heart disease pathology as
they relate to menopause. The murine ovariectomy model is used to illustrate the
proposed pathways of heart disease related to ovarian hormone loss in postmenopausal
women. Further, it is used to evaluate the effectiveness of countermeasures, such as
physical activity to reduce the negative consequences of ovarian hormone loss on the
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cardiovascular system. In this study, the mice received surgery at 8-10 weeks of age
(young adult) and were sacrificed 8 weeks post-surgery therefore this study evaluates the
early effects of menopause without the added effects of aging. Due to the early time
period investigated, we chose to use gene expression analyses as gene expression is a
sensitive technique that can identify early markers of dysfunction prior to translation and
protein expression. Classic markers of cardiac dysfunction, the fetal gene program, were
evaluated in addition to markers of RAAS activation and fibrosis. Importantly, this study
aimed to evaluate the effects of ovarian hormone loss without induction of hypertension
or acute pathological stress on the cardiovascular system. Therefore, our results will be
relevant to the independent effects of ovarian hormones on heart disease.
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CHAPTER 3
METHODS
3.1 Introduction
The primary aims of this study are to investigate the effects of ovariectomy and
exercise on cardiac dysfunction in mice. This chapter will outline the methodologies
planned to achieve these aims.
3.2 Animals
Mouse models exhibit similar responses to surgical procedures as humans (61,
66). Bilateral ovariectomy is the most common intervention in animals to simulate
physiology related to ovarian hormone loss (50). In mice, ovariectomy has been shown to
reduce circulating estradiol by 67% and does not cause hyperphagia, eliminating the
effect of overweight and obesity due to consumption (99, 115). Ovariectomy leads to loss
of all ovarian-derived hormones and therefore precludes analysis of the effects of any one
hormone; therefore, this model may be more representative of changes that occur with
menopause. As we propose to study early markers of cardiac dysfunction we will use two
cohorts of 8 week old (early adult) mice and investigate the effect of exercise at this
stage.
3.2.1 Cohort 1:
Hearts from twenty female C57/BL6 (Harlan) mice were obtained from a study
conducted at the University of Maryland (118). At 8-10 weeks of age, mice were divided
into two groups: a sham surgery group (SHAM; n=10) and a bilaterally ovariectomized
group (OVX; n=10). The mice in the SHAM group were anesthetized but the ovaries
were left intact. All mice were given ad libitum access to water and standard rodent chow
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(Purina Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed
in a temperature controlled room on a 12h light/dark cycle for eight weeks after surgery.
Food was removed from all groups 24 hours before mice were sacrificed and weighed.
Hearts and other tissues were harvested, snap frozen in liquid nitrogen, and stored at 80˚C until processing.
3.2.2 Cohort 2:
Hearts were obtained from a study conducted at the University of Maryland (45).
Similar to cohort 1, twenty 8-week old C57/BL6 (Harlan) cohort 2 mice were divided
into two groups: a sham operated group (SHAM) and a bilaterally ovariectomized group
(OVX). All mice were housed in cages for eight weeks and half of each group (n=5) was
provided a running wheel for voluntary exercise (EX). Exercise animals were
individually housed to measure each animal’s activity. Wheel revolutions were recorded
by a computer attached to a photocell on each wheel. Data was populated through
customized software (Lafayette Instruments, Lafayette, IN). The other half of the two
groups were housed in a standard cage with no wheel and were considered the sedentary
(SED).
All mice were given ad libitum access to water and standard rodent chow (Purina
Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed in a
temperature controlled room on a 12h light/dark cycle. Mice were removed from the
wheel cages 24 hours prior to sacrifice and food was removed from all groups at this time
as well. All mice were then sacrificed, weighed, and tissues were harvested, snap frozen
in liquid nitrogen, and stored at -80°C until processing. The study was approved by the
University of Maryland institutional Animal Care & Use Committee (IACUC).
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3.3 Tissue Analysis
3.3.1

Gene expression
RNA was isolated from the heart tissue using the Trizol method (63). Briefly, 50-

100mg of tissue was homogenized in 1ml Trizol and incubated at room temperature for 5
minutes. Then, 0.2ml chloroform was added to each sample, mixed, and incubated for 23 minutes. Samples were centrifuged to separate the aqueous from solid phases. The
aqueous phase was removed and RNA was precipitated through the addition 0.5ml of
isopropanol. Samples were incubated then centrifuged. The resultant RNA was washed
with a 75% ethanol solution then dried. RNA was then rehydrated and stored at -80°C.
RNA content was determined via spectrophotometry (NanoDrop).
To synthesize complementary DNA (cDNA), 0.2-1 μg of total RNA (depending
on the target gene) was reverse transcribed and the reaction was inactivated by incubation
at 70ºC for 15 minutes. Primers were designed for each target (Table 1) and optimized for
annealing temperature, dilution, and greater than 95% efficiency. Dissociation melt
curves were analyzed to determine the specificity of the PCR products. cDNA produced
from the reverse transcription reaction was mixed with SsoFast EvaGreen (BioRad), and
forward and reverse primers for each rtPCR reaction (Table 1). PCR was employed using
GAPDH as a reference for each reaction. GAPDH was evaluated as a reference gene by
statistical analysis of mean threshold (C(t)) values for each sample. For cohort 1, the
average C(t) values for each SHAM sample across all genes were compared with those
for each OVX sample using a two-tailed T-test (p=0.05). For cohort 2, intergroup
differences between the average C(t) values across all genes were determined with a two-
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way ANOVA. There was a significant effect of group and condition (p=0.013, 0.001), but
no significant group by condition interactions.
Quantification of gene expression in each treatment group was analyzed
according to the 2^∆CT method where the ∆CT = GAPDH CT - target gene CT. Data
was expressed normalized to the SHAM SED condition, which was set to 1.
3.3.2

Statistical Analysis
Data is expressed as means ± standard error. Both cohorts were tested for

normality and equal variance. Differences between groups in cohort 1 were determined
using two-tailed T-tests with Microsoft Excel. Due to limited sample size, cohort 2 did
not pass assumption tests. Cohort 2 served as a preliminary analysis, and SigmaPlot
Software was used to conduct an Analysis of Variance (ANOVA) to determine the effect
of group (OVX, SHAM) and the effect of condition (SED, EX). Significant interactions
were analyzed using Tukey’s post hoc testing. Significance was set at an alpha level of p
< 0.05.
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Primer
GAPDH
Atrial
Natriuretic
Peptide (ANP)
B-type
Natriuretic
Peptide (BNP)
α-Myosin
Heavy Chain
(α-MHC)
β-Myosin
Heavy Chain
(β-MHC)
α-Skeletal
Actin (α-sk )
Ca2+ ATPase
(SERCA2a)
Angiotensin II
(AngII)
Endothelin-1
(ET-1)

Transforming
Growth
Factor β1
(TGFβ-1)
α-Smooth
Muscle Actin
(α-sma)
Collagen 1
(Col1)

Table 1: Gene Expression Targets
Function
Primer Sequence (5’-3’)
Reference Gene
F: CTCATGACCACAGTCCATGC
R: CACATTGGGGGTAGGAACAC
Fetal Gene Program &
F: TGCCGGTAGAAGATGAGGTC
Cardiac Dysfunction
R: AGCCCTCAGTTTGCTTTTCA
Marker
Fetal Gene Program &
F: CTGAAGGTGCTGTCCCAGAT
Cardiac Dysfunction
R: CCTTGGTCCTTCAAGAGCTG
Marker
Fetal Gene Program &
F: CTGGGCAAATCCAACAACTT
Cardiac Dysfunction
R: TCTTGCCTCCTTTGCCTTTA
Marker
Fetal Gene Program &
F: TGCAGCAGTTCTTCAACCAC
Cardiac Dysfunction
R: TCGAGGCTTCTGGAAGTTGT
Marker
Fetal Gene Program &
F: CGATATCCGCAAAGACCTGT
Cardiac Dysfunction
R: GCTGGAAGGTGGACAGAGAG
Marker
Fetal Gene Program &
F: CTGTGGAGACCCTTGGTTGT
Cardiac Dysfunction
R: CAGAGCACAGATGGTGGCTA
Marker
Induces TGFβ secretion F: AGCAGCCGTCCTTTTGATAA
R: TGCTGGACACCTTTTTAGGG
Induces TGFβ secretion F: GTGTCTACTTCTGCCACCTGGAC
and Stimulates CFB
AT
Differentiation to MFB
R: GGGCTCGCACTATATAAGGGATG
AC
Stimulates CFB
F: ATACGCCTGAGTGGCTGTCT
Differentiation to MFB
R: GGTTCATGTCATGGATGGTG
Marker of MFB
formation

F: ACTGGGACGACATGGAAAAG
R: AGAGGCATAGAGGGACAGCA

ECM Fiber Involved in
Myocardial Remodeling

F:

TGACTGGAAGAGCGGAGAGT

R:
F:
R:
F:
R:
F:
R:

ATCCATCGGTCATGCTCTCT
GTCCACGAGGTGACAAAGGT
GATGCCCACTTGTTCCATCT
AAGGAAGAGATGGCTCGTCA
TTGAGTGGGTGTCAACCAGA
CAAGACCATACCTGCCGAAT
CAACTGGTTGGCATGAAATG

Collagen 3
(Col3)
Vimentin
(Vim)

ECM Fiber Involved in
Myocardial Remodeling
ECM Fiber Involved in
Myocardial Remodeling

Fibronectin
(FN)

ECM Fiber Involved in
Myocardial Remodeling
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CHAPTER 4
RESULTS
4.1 Cohort 1
4.1.1

Animal Characteristics
Cohort 1 heart weight and body weight information was provided by the

University of Maryland where the animals were sacrificed (117). The OVX group had
significantly greater body weight and significantly lower heart weight to body weight
ratio compared to SHAM (p<0.001; 0.001, respectively). There was no difference in heart
weight between groups (Table 2).

SHAM
(n=10)
OVX
(n=10)

Table 2: Animal Characteristics for Cohort 1
HW (g) SEM
BW (g) SEM HW/BW

SEM

0.1295

0.003

22.18

0.270 0.0058

0.0001

0.1250

0.004

25.33*

0.484 0.0049*

0.0001

* indicates significant difference from sham surgery (SHAM) female mice (p<0.005).

4.1.2

Gene Expression
Gene expression data for cohort 1 is depicted in fold change relative to the SHAM

group (set to 1.0) and the genes investigated have been grouped by function for clarity.
The first group of genes is the signature fetal gene program: ANP, BNP, α-MHC, βMHC, α-ska, and SERCA-2a. The second group of genes, angiotensin II, TGFβ-1,
endothelin-1, and α-sma are implicated in MFB activation and pathological fibrosis in the
heart. ECM fibers collagen 1 & 3, vimentin, and fibronectin comprise the third group and
are indicators of myocardial remodeling and fibrosis.
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4.1.3 Cohort 1: Fetal Genes
Cohort 1 expression of many of the fetal genes resembled the expression pattern
of the pathological model of heart disease (See Figure 3). ANP and BNP, cardiac
hormones that respond to stretch, showed greater expression (3.43-fold, p=0.063 and
2.52-fold, p=0.026, respectively) in the OVX group. Expression of contractile filaments
α-MHC and β-MHC was significantly lower in OVX (0.79-fold, p=0.048 and 0.64-fold,
p=0.007, respectively) compared to SHAM. The skeletal muscle component α-ska
showed 1.62-fold greater gene expression in the OVX group (p=0.007) while the calcium
handling protein Serca-2a showed a 0.735-fold downregulation compared to SHAM
(p=0.444)(Figure 5).
5
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SHAM

mRNA Level

4

OVX

*

3.5
3
2.5
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1.5

*
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Figure 7: Expression of fetal genes (Cohort 1) Atrial Natriuretic Peptide (ANP), B-type
Natriuretic Peptide (BNP), α-Myosin Heavy Chain (α-MHC), β-Myosin Heavy Chain (βMHC), α-Skeletal Actin (α-ska), and Calcium ATPase (SERCA 2a) depicted as fold change of
ovariectomized (OVX) female mice (n=10) compared to sham surgery (SHAM) female mice
(n=10). * indicates that OVX expression was significantly different from SHAM (p<0.05).
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4.1.4 Cohort 1: Fibrotic Markers
Mediators of pathological fibrosis showed greater expression in ovariectomized
mice compared to the sham group. Angiotensin II was 5.28-fold higher in OVX
(p=0.021) and expression of TGFβ-1 in OVX was 2.97-fold greater than SHAM
expression (p = 0.017). Expression of endothelin-1, a mediator of fibrosis involved in
stimulating MFB formation, was 1.7-fold greater in OVX, but this was not statistically
significant (p=0.255). The MFB marker α-sma mRNA levels were 1.89-fold higher in
OVX compared to SHAM (p=0.057) (Figure 6).
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Figure 8: Gene expression of fibrotic markers (Cohort 1) Angiotensin II (AngII), Endothelin-1 (ET1), Transforming Growth Factor β1 (Tgfβ1), and α-Smooth Muscle Actin (α-sma) depicted as fold
change of ovariectomized (OVX) female mice (n=10) compared to sham surgery (SHAM) female
mice (n=10). * indicates that OVX expression was significantly different from SHAM (p<0.05).

4.1.5 Cohort 1: ECM fibers
Expression of extracellular matrix fibers was higher in OVX mice compared with
SHAM, although not statistically significant. Collagen 1 and collagen 3 showed 2.16- and
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2.47-fold higher expression in OVX compared to SHAM (p=0.099; 0.065, respectively).
OVX also exhibited 2.16-fold greater expression of vimentin and fibronectin was
upregulated 3.23-fold compared to SHAM (p=0.99; 0.062, respectively) (Figure 7).
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Figure 9: Gene expression of ECM fibers (Cohort 1) Collagen 1 (Col1), Collagen 3 (Col3),
Vimentin (Vim), and Fibronectin (FN) depicted as fold change of ovariectomized (OVX)
female mice (n=10) compared to sham surgery (SHAM) female mice (n=10).

4.2 Cohort 2
4.2.1

Animal Characteristics
Body weight, heart weight, and food consumption data for cohort 2 animals was

provided by the University of Maryland, where the animals were sacrificed (45, 117).
There was no effect of ovariectomy or exercise on heart weight between groups.
Ovariectomy had a significant effect on body weight and food consumption (p=0.039 and
p=0.027, respectively). Exercise had a significant effect on food consumption as well
(p=0.037). Running data was not acquired on this cohort.

Data that was collected

previously on a similar cohort of animals reveals reduced running distance in OVX
compared with SHAM (Appendix A) (118).
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Table 3: Animal Characteristics for Cohort 2

SHAM
SED
(n=5)
OVX SED
(n=5)
SHAM EX
(n=5)†
OVX EX
(n=5)†

HW (g)

BW (g)

HW/BW

0.1380

24.19

0.0057

Average Food
Consumption (g)
4.943

0.1282

26.73

0.0048

4.229

0.1492

24.15

0.0062

5.189

0.1555

25.81

0.0060

4.912

There were no significant interactions between group and condition. †Note: This data
represents the full cohort. A sample from both SHAM EX and OVX EX groups was lost
during shipping and is not included in the gene expression data below.

4.2.2 Gene Expression
Gene expression for cohort 2 is depicted in fold change relative to the SHAM
group (set to 1.0). The gene targets have been grouped by function for clarity with the
first group consisting of the signature fetal gene program: ANP, BNP, α-MHC, β-MHC,
α-ska, and SERCA-2a. The second group consists of angiotensin II, TGFβ-1, endothelin1, and α-sma; genes implicated in MFB activation and pathological fibrosis in the heart.
ECM fibers collagen 1 & 3, vimentin, and fibronectin comprise the third group and are
associated with cardiac remodeling and fibrosis.

4.2.3 Cohort 2: Fetal Genes
Expression levels are depicted in fold change relative to the sham sedentary group
(set to 1.0) and the genes have been organized in the same grouping as that of cohort 1.
Cohort 2 fetal gene expression showed the influence of exercise on ovariectomized mice.
There was no effect of ovariectomy or exercise on cardiac gene expression of ANP and
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BNP. Both group and condition had significant effects on cardiac mRNA expression of
myosin isoform α-MHC (p=0.008, 0.001) as well as a significant group by condition
interaction (p=0.008). α-MHC expression was significantly upregulated in OVX SED and
SHAM EX compared to sham sedentary (2.07-fold, p=0.001 and 2.34-fold, p=0.001,
respectively). There was a significant group effect (p=0.006) and group by condition
interaction (p=0.001) on gene expression of β-MHC. OVX SED and SHAM EX had
greater mRNA expression of β-MHC compared to SHAM SED (2.11-fold, p=0.001 and
1.49-fold, p=0.039, respectively). OVX EX expression of β-MHC was significantly lower
than OVX SED (1.37-fold, p=0.04). Gene expression of skeletal muscle isoform α-ska
showed a significant overall effect of exercise (p=0.013). There was a significant effect
of group and condition on gene expression of contractile protein SERCA 2a (p=0.001,
0.001).
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Figure 10: Expression of fetal genes (Cohort 2) Atrial Natriuretic Peptide (ANP), B-type Natriuretic
Peptide (BNP), α-Myosin Heavy Chain (α-MHC), β-Myosin Heavy Chain (β-MHC), α-Skeletal Actin
(α-ska), and Calcium ATPase (SERCA 2a) depicted as fold change of ovariectomized sedentary (OVX
SED) female mice (n=5), ovariectomized exercise (OVX EX) female mice (n=4), and sham surgery
exercise (SHAM EX) female mice (n=4) compared to sham surgery sedentary (SHAM SED) female
mice (n=10). * indicates fold change was significantly different from SHAM SED, θ indicates
significant difference from OVX SED, and  indicates significant difference from SHAM EX (p<0.05).

4.2.4 Cohort 2: Fibrotic Markers
There was a significant effect of ovariectomy and exercise on gene expression of
Angiotensin II, a mediator of cardiac fibrosis (p=0.016, 0.015). Angiotensin II expression
also had a group by condition interaction and OVX EX hearts had significantly greater
expression of AngII compared to OVX SED and SHAM EX (4.15-fold, p=0.001, 0.001).
Gene expression of endothelin-1, another fibrotic mediator, showed a significant effect of
ovariectomy (p=0.043). TGFβ-1, involved in cardiac growth and remodeling, and α-sma,
a marker of MFB formation, both showed no significant effects of group or condition
(Figure 10).
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Figure 11: Gene expression of fibrotic markers (Cohort 2) Angiotensin II (AngII), Endothelin-1 (ET1), Transforming Growth Factor β1 (Tgfβ1), and α-Smooth Muscle Actin (α-sma) depicted as fold
change of ovariectomized sedentary (OVX SED) female mice (n=5), ovariectomized exercise (OVX
EX) female mice (n=4), and sham surgery exercise (SHAM EX) female mice (n=4) compared to
sham surgery sedentary (SHAM SED) female mice (n=10). * indicates fold change was significantly
different from SHAM SED, θ indicates significant difference from OVX SED, and  indicates
significant difference from SHAM EX (p<0.05).

4.2.5 Cohort 2: ECM fibers
ECM fibers, indicators of cardiac fibrosis and tissue remodeling, followed a
relatively consistent pattern of expression. Collagen 3 gene expression had a significant
overall effect of exercise (p=0.048). There was no effect of group or condition on cardiac
gene expression of collagen 1, vimentin, or fibronectin (Figure 12).
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Figure 12: Gene expression of ECM fibers (Cohort 2) Collagen 1 (Col1), Collagen 3 (Col3),
Vimentin (Vim), and Fibronectin (FN) depicted as fold change of ovariectomized (OVX) female
mice (n=10) compared to sham surgery (SHAM) female mice (n=10).

37

CHAPTER 5
DISCUSSION
Ovarian hormone loss after menopause is associated with an increased risk for
heart disease and coronary events. In this study, we were interested in cardiac gene
expression patterns at early stages of ovarian hormone loss in a postmenopausal animal
model. We also explored exercise as a possible modality for attenuating ovariectomy
induced changes in cardiac expression. We hypothesized that ovariectomy would cause a
pathological cardiac gene expression pattern and fibrosis and that voluntary wheel
running would be related to lower expression markers of dysfunction. Our major findings
were 1) compared to sham surgery mice, ovariectomized mice expressed a disease
phenotype of the cardiac fetal gene program, 2) ovariectomized mice upregulated cardiac
expression of ECM genes and other genes associated with fibrosis, which may be related
to increased angiotensin II expression and 3) exercise reduced the expression of many
fibrosis-associated genes.
5.1 Ovariectomy Causes Activation of the Fetal Gene Program
Adult re-expression of the fetal gene program in cardiac tissue is a wellcharacterized key indicator of heart disease (79, 84, 107). Acute injury or chronic
systemic stressors produce an environment of hypoxia and increased hemodynamic load
resulting in compensatory cell hypertrophy in the heart. These pathological changes
mimic the low oxygen environment and growth-induced wall strain of the fetal heart,
resulting in the reemergence of fetal expression signature in the diseased heart (84, 107).
Activation of the fetal gene program has been characterized in various heart disease
models, including hypertension, myocardial infarction, and heart failure, but it is
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unknown whether the expression pattern is an early indicator of cardiac dysfunction in
postmenopausal women (8, 20, 79, 107).
In this study, intergroup differences in mRNA levels of fetal genes show that only
8 weeks of ovarian hormone loss caused changes in cardiac gene expression.
Ovariectomized mice had greater mRNA levels of cardiac stretch hormones ANP and
BNP compared to sham mice, suggesting that ovarian hormone loss is associated with
changes indicative of increased cardiac stretch. Though we cannot confirm this with
mechanical data on the degree of chamber stretch or wall strain or blood pressure in these
animals, the data suggest that OVX was associated with altered natriuretic peptide
maintenance of blood pressure homeostasis.
In normal physiological conditions, cardiac expression of ANP and BNP
functions to counterbalance the renin angiotensin aldosterone system (RAAS), primarily
by activating guanylyl cyclase-A (GC-A), which promotes vasorelaxation, natriuresis,
and diuresis when active (15, 21, 38, 52, 83). ANP and BNP also suppress the RAAS by
reducing plasma renin activity and ANP is able to directly inhibit renin production in the
kidneys, providing a direct hormonal link between the heart and renal system (15, 57,
75). In pathological cases of hypertension and heart failure, this balance is lost and
natriuretic peptide expression increases as RAAS activity escalates (15).
This pathological failure of homeostasis may also be a product of postmenopausal
ovarian hormone loss as an increasing amount of evidence suggests that estrogen is a
critical regulator of the RAAS (119). Estrogen controls synthesis of angiotensinogen, an
upstream precursor of AngI and AngII that is activated by renin (53). Studies have found
that compared to E2-replete counterparts, E2 deficient rats as well as postmenopausal
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women have higher levels of circulating plasma renin and have greater activity of
angiotensinogen-converting enzyme (ACE), the enzyme that regulates AngII production.
Additionally, E2-deficient hypertensive rats have greater levels of circulating AngII
compared to E2-replete counterparts (27, 119). These studies show that estrogen
regulates production of angiotensinogen and conversion to angiotensin II by regulating
enzyme activity. As a result, estrogen is able to modulate RAAS activity and prevent
homeostatic imbalance and pathological upregulation of natriuretic peptides in the heart.
Our data suggests that ovarian hormone deficiency led to increased RAAS
activity as cohort 1 OVX mice had 5.28-fold greater levels of cardiac AngII mRNA
compared to SHAM mice and greater cardiac natriuretic peptide expression pattern in the
hearts of ovariectomized mice. Surprisingly, the negative effects of ovarian hormone loss
on the heart occurred within only 8 weeks of ovariectomy.

Increased adiposity,

expression of systemic inflammatory markers, and other the systemic changes associated
with ovariectomy may also have increased cardiac strain and resulted in ANP and BNP
upregulation (60). The degree of wall strain and the mechanics of cardiac chamber
dilation in a model of ovarian hormone loss should be investigated to further understand
the effects of postmenopausal physiology on cardiac pathology.
Our data revealed additional indicators that OVX animals experienced cardiac
dysfunction compared with SHAM animals.

OVX mice expressed lower levels of

cardiac contractile protein isoforms α-MHC and β-MHC compared to SHAM mice.
Downregulation of α-MHC and greater prevalence of β-MHC is the disease-associated
re-expression of a fetal pattern in mice hearts. Changes in myosin heavy chain expression
have been established in models of acute stress or extreme cardiac dysfunction. Studies of
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pressure/volume overload and spontaneous hypertension in rat models showed a
significant transition in cardiac gene expression from predominantly α-MHC to the
disease-associated β-MHC (42, 107). These models involved drastic perturbations to
cardiac homeostasis; the myosin heavy chain expression pattern in cohort 1
ovariectomized mice may have not been affected as severely after only 8 weeks of
ovarian hormone loss; and therefore, only an upregulation of β-MHC was observed
without a downregulation of α-MHC. Potentially, the upregulation of β-MHC precedes
the downregulation of α-MHC during the earliest stages of cardiac dysfunction.
McMullen et al. reported that the calcium handler SERCA 2a mRNA expression
was downregulated in a model of cardiac pressure overload indicating that calcium
reuptake from the sarcoplasmic reticulum suffers in a model of cardiac dysfunction (71).
Other animal models of induced hypertrophy have shown radical upregulation of
SERCA-2a, suggesting that calcium handling exhibits a bimodal response to cardiac
stress. Initial increases in SERCA-2a levels are hypothesized to be part of an energyconserving mechanism in environments of mild cardiac stress; though some studies have
shown discrepancies in SERCA-2a regulation with mild hypertrophy (1). In cohort 1 of
our study, there were no significant differences in SERCA-2a gene expression between
OVX and SHAM mice indicating that calcium handling was not affected by 8 weeks of
ovarian hormone loss. Future studies should examine whether contractile dysfunction and
SERCA-2a upregulation is initiated in a model of ovarian hormone loss at later time
points.
The expression of muscle filament α-ska was significantly greater in OVX mice
compared to sham, suggesting a transition from cardiac actin to the skeletal muscle
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isoform. Skeletal actin is predominantly expressed during fetal heart growth periods, and
the re-emergence of this expression pattern has been documented throughout the
progression of cardiac hypertrophy and heart disease (5, 8, 42, 107). Upregulation of αska may show an effect of short term ovarian hormone loss on heart muscle filament
expression that resembles the stress-inducing effects of fetal growth and heart disease.
5.2 Ovariectomy Activates Cardiac Fibrosis Associated Genes
Cardiac tissue fibrosis is associated with pathological remodeling of the
myocardium in response to increased total peripheral resistance, cardiac hypertrophy, and
acute cardiac injury such as a myocardial infarction (24, 96). These risk factors increase
the volume load on the heart and in order to achieve the necessary contractile strength,
cardiac myocytes begin to hypertrophy. The accompanied infiltration of inflammatory
cells as well as the muscle growth increases intercellular space (124). Resident cells,
predominantly cardiac fibroblasts (CFBs), upregulate protein expression of ECM fibers
in order to maintain wall structure and proper contractility (24, 48). While the heart is
able to compensate this way for some time, increased cardiac hypertrophy and fibrosis
can lead to maladaptive chamber dilation and wall stiffening, eventually resulting in
contractile dysfunction. We aimed to explore if ovarian hormone loss and the associated
systemic physiological changes induced cardiac fibrosis or initiated mRNA expression of
profibrotic markers in the heart. Assessing transcription of profibrotic genes in
ovariectomized mice could provide a strong link between the effects of ovarian hormone
loss on heart tissue and the increased risk of heart disease after menopause. The majority
of the literature has explored increases in ECM fiber deposition and myofibroblast (MFB)
formation using models of acute cardiac injury or induced spontaneous hypertension,
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showing that ovarian hormones such as estrogen can reduce pathological remodeling of
the heart (23, 80, 81, 110). Our mouse model can help elucidate fibrosis-associated
changes caused by ovarian hormone loss alone; without the effects of acute injuries,
hypertension, or transgenically induced diseases.
Analysis of gene expression data revealed that ECM fiber expression was affected
by ovarian hormone loss. Cardiac expression of collagen 1 and collagen 3 was 2.16- and
2.47-fold greater in ovariectomized mice compared to mice with sham surgery. Both
collagen isoforms are present in the ECM of a healthy myocardium, but prolonged or
drastic upregulation of collagen fibers is indicative of pathological fibrosis. An integral
part of maladaptive fibrosis is the differentiation of CFB cells into the MFB phenotype
and the initial stage of this differentiation process is characterized by the formation of an
intercellular matrix that is dense with collagen. As differentiation progresses, these protomyofibroblasts also begin to secrete fibronectin and vimentin fibers that infiltrate the
ECM (9, 10). Cardiac gene expression of fibronectin and vimentin was 3.23- and 2.16fold greater in OVX mice compared to mice that underwent sham surgery. This
upregulation may be a product of preliminary shifts in the CFB phenotype resulting from
ovarian hormone loss and associated systemic changes.
The estrogen-controlled RAAS is part of a possible mechanism that provides a
relationship between ovarian hormone loss and changes in ECM fiber gene expression;
this pathway may also explain the effects of postmenopausal physiology on cardiac
dysfunction in women (15, 119). Apart from balancing natriuretic peptide activity, AngII
(circulating and local) is an upstream activator of TGFβ-1 in cardiac fibroblasts, which
promotes fibrosis and CFB differentiation (87). Higher levels of cardiac AngII mRNA in
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ovariectomized mice may have stimulated TGFβ-1 expression, which was 2.97-fold
greater in OVX compared to SHAM. In pathological cardiac fibrosis, TGFβ-1 acts via a
SMAD pathway to initiate CFB differentiation to an MFB cell type (58, 59, 62, 81). The
activation of this pathway by RAAS hyperactivity in ovariectomized mice could provide
a mechanism for the ECM fiber expression results found in cohort 1.
There were no intergroup significant differences in gene expression of endothelin1 and α-smooth muscle actin, two markers that characterize MFB differentiation and
cardiac tissue fibrosis. The hearts of the ovariectomized mice may be expressing early
signs of cardiac dysfunction that precede myocardial remodeling. The mice were
sacrificed 8 weeks post surgery and this early time point highlights the influential role of
ovarian hormones on cardioprotection. More importantly, the reduction in circulating
ovarian hormones may impact cardiac function in women at early stages post menopause.
Differences in expression levels of genes associated with fibrosis and ECM fiber
deposition provide preliminary information regarding the effects of ovarian hormone loss
on cardiac health. Future studies with analysis of protein expression and ECM thickness
can provide more information regarding physical changes in the myocardium.
5.3 Exercise inhibits a pathological gene expression pattern with ovariectomy
Physical activity has been shown to improve cardiac function, diminish
pathological myocardial remodeling, and lower the risk for heart disease (39). Using
cohort 2, we investigated the effects of physical activity on the pathological cardiac
expression pattern. With swim training, McMullen et al. found that mouse cardiac gene
expression of ANP and BNP were lower compared with sedentary animals, exhibiting a
healthy adult pattern, thus demonstrating the potential benefits of exercise on lowering
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markers of cardiac dysfunction (71). In cohort 2, we found no effect of group or
condition on cardiac ANP and BNP gene expression; despite high standard error, ANP
expression is 2.08-fold greater in hearts of OVX SED mice compared to SHAM SED.
Between the two natriuretic hormones, ANP plays a greater role in RAAS regulation than
BNP. ANP directly inhibits renin secretion from the juxtaglomerular cells of the kidneys
and functions to maintain natriuresis and dieresis by inhibiting RAAS hyperactivity (15).
Research shows that exercise improves renal function and is effectively able to prevent,
reduce, and delay chronic kidney disease. ANP expression may have been downregulated
as exercise was able to regulate RAAS activity.
On the other hand, in a study investigating fetal gene reactivation in 8 week old
treadmill trained rats, Kemi et al. found that after 6 weeks, cardiac expression of ANP
was not different between trained and sedentary groups (51). In this study, animals were
not diseased. The re-expression of fetal genes has been established as a sign of
pathological changes in cardiac tissue, while exercise associated physiological changes in
cardiac expression follow a distinctly separate pathway (42, 51, 107).
There was a significant group by condition interaction in expression of α-MHC
and β-MHC though contrary to cohort 2 results, cohort 1 OVX SED mice expressed
greater levels of cardiac α-MHC and β-MHC compared to SHAM SED. The increase in
expression of β-MHC with ovariectomy may illustrate the pathological effects of ovarian
hormone loss on myosin heavy chain isoform expression in cardiac tissue. With exercise,
ovariectomized mice showed significantly lower mRNA expression of β-MHC compared
to sedentary counterparts, suggesting a cardioprotective role of exercise that influences
myosin heavy chain isoform expression in the heart. The greater β-MHC expression in
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the SHAM EX group compared to SHAM SED may be a result of low sample size and
high variability between individual mice. These limitations may also explain the
expression pattern of α-ska, which showed no significant difference with ovariectomy,
unlike the results of cohort 1 samples. Gene expression of α-ska was not different
between sedentary and exercise conditions, which mirrors findings by Kemi et al.
wherein cardiac mRNA expression of α-ska showed no significant differences between
sedentary and treadmill trained rats.
Calcium handling in the heart becomes compromised with cardiac injury and the
associated pathological response. McMullen et al showed that SERCA 2a, a calcium
handler in cardiac tissue, is downregulated in the disease model compared to sham
surgery and that exercise showed mRNA expression similar to sham (5, 71). The fetal
gene program and calcium handling in particular has not been characterized in a model of
ovarian hormone loss. Cohort 2 showed greater SERCA 2a expression with ovariectomy
and lower expression with exercise. The expression pattern found with cohort 2 may be a
compensatory mechanism for the systemic stress associated with postmenopausal
physiology.
5.4 Exercise may play a role in limiting pathological remodeling of the myocardium
Exercise induced physiological cardiac hypertrophy and remodeling occurs
through molecular pathways involving growth factors and other signaling molecules
distinct from the inflammatory pathways activated in pathological myocardial fibrosis
(51). This beneficial adaptation results from sustained exercise training, is associated
with normal or improved heart function, and is a reversible process (5). We hypothesized
that mice exposed to voluntary wheel running would express lower levels of cardiac
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markers associated with fibrosis and genes coding for ECM proteins compared to the
sedentary counterparts within OVX and SHAM groups. There was a significant group by
condition interaction in cardiac gene expression of Angiotensin II and OVX EX mice
hearts had 4.15-fold greater AngII expression compared to OVX SED and SHAM EX
(p=0.001). Physical activity is associated with decreased plasma renin activity and
lowered levels of circulating AngII in models of heart failure (126). Circulating
angiotensin and activation of RAAS balances natriuretic peptide release from the heart to
regulate blood pressure in normal physiology (89, 121). The AngII expression pattern in
cohort 2 may differ from our initial hypothesis because of lower levels of ANP and BNP
in the exercise conditions. ET-1 and Tgfβ-1, mediators of MFB formation, had similar
expression patterns as α-sma, a characteristic marker of MFB cells, that may indicate
activation of the differentiation pathway. There was a significant group effect (p=0.043)
on ET-1 expression in cohort 2. There was a general pattern of ET-1, Tgfβ-1, and α-sma
upregulation with ovariectomy and slight downregulation with exercise, indicating that
exercise may influence the pathological differentiation of cardiac fibroblasts at early
stages of ovarian hormone loss.
Exercise has been shown to reduce myocardial remodeling and fibrosis in
ovariectomized spontaneously hypertensive rats. The expression pattern of ECM fibers in
cohort 2 suggests that physical activity may also influence myocardial remodeling in an
ovariectomized rodent model that is not subject to a major insult to the heart. Gene
expression of ECM proteins followed a similar pattern of expression as ET-1, Tgfβ-1,
and α-sma. There was a significant effect of condition on collagen 3 gene expression as
this ECM fiber was downregulated in the exercise condition (p=0.048). Though collagen
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1, vimentin, and fibronectin mRNA levels did not have significant effects of group or
condition, the overall expression pattern of all four ECM fibers was consistent. Cardiac
gene expression of Col1, Col3, Vim, and FN was greater in OVX SED mice compared to
SHAM SED and was lower in the exercise conditions. This expression pattern suggests
that the early pathological effects of ovarian hormone loss on cardiac gene expression can
be attenuated for with exercise within a short period of time, highlighting the importance
of physical activity in terms of disease prevention.
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CHAPTER 6
CONCLUSION
The American Heart Association reports that as of 2013, 26% of women age 45 and
older who have an initial recognized MI die within a year compared to 19% of men,
mainly because women are more likely to suffer a heart attack later in life compared to
men (28). This disparity between males and females illustrates the cardioprotective role
of ovarian hormones and the importance of establishing the effects of menopause. We
hypothesized that the hearts of ovariectomized mice would upregulate gene expression of
markers of cardiac dysfunction and pathological fibrosis and that exercise would be able
to lower the expression of these markers. Based on our results we found that OVX hearts
did manifest early signs of cardiac dysfunction and expressed greater mRNA levels of
profibrotic markers.
As of 2015, approximately 20% of the United States population is between 50-64
years of age as the country undergoes a demographic transition to an aging society.
Seventy percent of this population enters their 60s previously diagnosed with at least one
chronic condition (28). As a result, the disease burden of the aging population and
associated healthcare costs are due to increase over the next few years and in order to
diminish this amount of waste and improve quality of life for a large portion of the
population, effective early interventions need to be assessed and established. Physical
activity is not only associated with improved cardiac function, but is able to diminish
insult-induced cardiac dysfunction and fibrosis in animal models of ovarian hormone
loss. Despite limitations, cohort 2 data supported the finding that ovariectomy increased
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expression of cardiac dysfunction markers and that exercise was able to attenuate for
some of these gene expression differences.
The mice in this study were sacrificed 8 weeks post surgery, at a young adult age
(16 weeks old), which shows that even a limited period of ovarian hormone loss affected
cardiac expression pattern and activated a fetal expression program, indicating heart
disease pathology. Cardiac fibrosis and myocardial remodeling has been well established
in models of acute cardiac injury or advanced stages of hypertension and heart disease
(33, 96, 105). Our novel findings showed that mRNA levels of profibrotic markers and
ECM fibers were upregulated in ovariectomized mice compared to sham. The effect of
short term ovarian hormone loss on cardiac gene expression highlights the relationship
between postmenopausal physiology and the increased risk for heart disease and
necessitates the early timing of healthy preventative measures such as exercise. The CDC
has reported that 1 in 3 female deaths is caused by heart disease and as this risk increases
drastically after menopause, it is important to understand the immediate effects of ovarian
hormone loss when determining treatment options.
6.1 Strengths and Limitations
Most studies assessing expression patterns of fetal genes and cardiac fibrosis use
models of acute or direct injury to the heart. Strengths of this study include the use of
ovariectomy to replicate post menopausal physiology in order to investigate changes in
expression of cardiac dysfunction markers due to the systemic changes associated with
ovarian hormone loss. More importantly, this model was able to assess pathological
effects of ovarian hormone loss on the heart at early time points, highlighting the degree
of cardioprotection of ovarian hormones as well as the need for early intervention

50

methods to reduce the risk of heart disease in postmenopausal women. By investigating
differences in gene expression, we were able to observe early changes in the heart caused
by postmenopausal physiology.
This study is not without limitations. Cohort 2 consisted of a limited number of
animals, with five mice in each of the sedentary conditions (OVX and SHAM) and only
four mice in each of the exercise conditions. The low sample size as well as other
methodological differences between cohorts likely resulted in high individual variability
and as a result some of the OVX versus SHAM comparisons in cohort 2 contradict
findings with cohort 1. Primarily, cohort 1 animals were housed in groups together while
cohort 2 animals were housed individually. Studies have shown that rodents prefer a
group living dynamic and exhibit increased heart rate when housed individually (2, 101).
Additionally food consumption was monitored in cohort 2 and animals may have had
more human contact as food was removed for weighing daily.
6.2 Future Directions
Future research should use Western Blot or immunohistochemistry to investigate
ECM protein expression as well as the differences in cardiac fibrosis in the hearts of
ovariectomized mice compared to sham. Mouse echocardiography can also be utilized in
order to determine the timing of symptoms indicating cardiac dysfunction in models of
ovarian hormone loss. Establishing early effects of ovarian hormone loss on cardiac
dysfunction markers can help develop possible preventative interventions, such as
exercise, to reduce the risk of heart disease that is correlated with ovarian hormone loss.
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APPENDIX
RUNNING DATA
Wheel running had been recorded for the cohort 2 subgroups in the EX condition;
however the recorded data was lost and unable to be recovered during the original study.
Running data below was collected from a study with a similar animal protocol at
University of Maryland with previously published results (118). This study was
conducted on C57/BL6 mice that were divided into sedentary and exercise cohorts. At 8weeks old, eleven mice were divided into two groups: a sham surgery group (SHAM,
n=5) and a bilaterally ovariectomized (OVX, n=6). For 8 weeks, all mice were housed in
individual cages that contained a voluntary wheel for exercise. Wheel revolutions were
recorded by a computer attached to a photocell on each wheel. Data was populated
through customized software (Lafayette Instruments, Lafayette, IN).
All mice were given ad libitum access to water and standard rodent chow (Purina
Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed in a
temperature controlled room on a 12h light/dark cycle. Mice were removed from the
wheel cages 24 hours prior to sacrifice and food was removed from all groups at this time
as well. Tissues were harvested, snap frozen in liquid nitrogen, and stored at -80°C until
processing. The study was approved by the University of Maryland institutional Animal
Care & Use Committee (IACUC).
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*

Recorded running data for two groups; * indicates significant difference
from sham surgery group (p<0.05).
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